PDCD1 and neoplasm: To test whether TMV vaccine inhibits the growth of the highly aggressive MOC2 tumor growth, we administered mice with MOC2 TMV vaccine every five days starting day 3 after tumor challenge and mouse anti-mouse PD-1 antibody (kind gift from Dr. Gordon Freeman) starting on day 8 after tumor challenge, as described in Figure 5A. The data suggest that MOC2 tumor growth is not affected by anti-PD-1 antibody (Figure 5B), which is consistent with earlier studies [38] and our own studies using rat anti-mouse PD-1 antibody.